Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma

Patients with a diverting stoma who receive adjuvant chemotherapy with fluoropyrimidines and oxaliplatin are at higher risk of severe digestive toxicities when treated with the CAPOX regimen. The mFOLFOX6 regimen appears to be safer alternative in this population.